U.S. Non-Invasive Prenatal Testing Market Research and Outlook, 2021 - Trends, Growth Opportunities, Competitive Analysis and Forecasts to 2028

Publisher Name :
Date: 25-Jun-2021
No. of pages: 140

The United States Non-Invasive Prenatal Testing (NIPT) market is expected to touch a valuation of USD 2.5 Billion by 2028.

The U.S. Non-Invasive Prenatal Testing market is growing with the increasing per capita income, growing interest, increase in incidences of chromosomal aneuploidies among fetus, development of advanced non-invasive prenatal testing products, rising awareness regarding non-invasive prenatal testing, rising focus on reimbursement for NIPT, increasing preference for non-invasive techniques over invasive methods and ACOG guidelines recommend NIPT for all pregnancies regardless of risk. The market shows high potential for growth in the future.

This new market report presents a comprehensive study of the entire United States non-invasive prenatal testing market. The report offers the most up–to–date industry data on the actual market situation and future outlook for the United States' non-invasive prenatal testing market. The report also provides up–to–date historical market size data for the period 2015 – 2020 and an illustrative forecast to 2028 covering key market aspects like market value and volume for non-invasive prenatal testing in the United States.

This Comprehensive Report Provides:


  • To Analyse the Historical Growth in the Market Size of the United States Non–Invasive Prenatal Testing Market from 2015 to 2020.

  • To Estimate and Forecast the Market Size of the United States Non–Invasive Prenatal Testing Market from 2021 to 2028 and Growth Rate until 2028.

  • The Market Size of the United States Average Risk Non–Invasive Prenatal Testing Market with Seven Years Forecast

  • The Market Size of the United States High-Risk Non–Invasive Prenatal Testing Market with Seven Years Forecast

  • Evaluates the Number of NIPT Tests Performed in the United States with Seven Years Forecast

  • Studies the United States Number of Average Risk NIPT Tests Performed with Seven Years Forecast

  • Examines the United States Number of High-Risk NIPT Tests Performed with Seven Years Forecast

  • Assessment of Market Potential and Opportunities for this Innovation-Driven United States Non–Invasive Prenatal Testing Market with Seven Years Forecast

  • Insights into the United States Average and High-Risk Potential NIPT Tests Market with Seven Years Forecast

  • Meticulously Assesses the Overall United States Potential Non–Invasive Prenatal Testing (NIPT) Volume and Future Trends

  • Analyses of the United States Average and High-Risk Potential Number of Tests Performed with Seven Years Forecast

  • Detailed Insights into the Regulatory Framework of the United States Non–Invasive Prenatal Testing Market

  • Features Reimbursement Patterns of the United States Non–Invasive Prenatal Testing Market

  • Tracks Competitive Developments, Approaches, Recent Industry Developments, Mergers & Acquisitions, Collaboration Deals, Partnership Deals, Distribution, Exclusive, and Licensing Agreement

  • A Comprehensive List of the Key Players Along with the Analysis of their Current NIPT Test Portfolios, Business Overview, and Recent Development


The Leading Companies for the United States Non–Invasive Prenatal Testing Market are Listed Below:


  • Illumina

  • Natera

  • Quest Diagnostics

  • Myriad Genetics

  • Centogene

  • GenPath

  • Progenity

  • PerkinElmer

  • Yourgene Health

  • Invitae Corporation

  • Agilent Technologies

  • Ariosa Diagnostics (Roche)

  • Integrated Genetics (LabCorp)


Key Questions Answered in this Report:


  • What is the current scenario of the United States non–invasive prenatal testing market?

  • What is the total market size and forecast (until 2028) for the United States non–invasive prenatal testing market?

  • How has the potential market performed so far and how will it perform in the coming years?

  • How many NIPT tests being performed in the U.S. during 2015 – 2028?

  • What is the market size of the average risk NIPT tests in the United States?

  • What is the market size of the high-risk NIPT tests in the United States?

  • What are the key marketed NIPT tests available in the United States?

  • What are the major drivers of the United States non–invasive prenatal testing market?

  • What are the major inhibitors of the United States non–invasive prenatal testing market?

  • What is the reimbursement pattern in the United States non–invasive prenatal testing market?

  • What is the regulatory framework in the United States non–invasive prenatal testing market?

  • What are the major deals and agreement happenings in the United States non–invasive prenatal testing market?

  • Who are the top market players? What are their happenings, current developments, and scenarios?

  • How is the market predicted to develop in the future?

U.S. Non-Invasive Prenatal Testing Market Research and Outlook, 2021 - Trends, Growth Opportunities, Competitive Analysis and Forecasts to 2028

Table of Contents

1. Executive Summary

2. United States Actual Non–Invasive Prenatal Testing Volume (Number of Tests Performed) and Forecast (2015 - 2028)
2.1 Average Risk Actual NIPT Test Volume (Number of Tests Performed) and Forecast
2.2 High-Risk Actual NIPT Test Volume (Number of Tests Performed) and Forecast

3. United States Potential Non–Invasive Prenatal Testing Volume (Number of Tests Performed) and Forecast (2015 - 2028)
3.1 Average Risk Potential NIPT Test Volume (Number of Tests Performed) and Forecast
3.2 High-Risk Potential NIPT Test Volume (Number of Tests Performed) and Forecast

4. United States Actual Non–Invasive Prenatal Testing Market Size and Forecast (2015 - 2028)
4.1 Average Risk Actual NIPT Test Market Size and Forecast
4.2 High-Risk Actual NIPT Test Market Size and Forecast

5. United States Potential Non–Invasive Prenatal Testing Market Size and Forecast (2015 - 2028)
5.1 Average Risk Potential NIPT Test Market Size and Forecast
5.2 High-Risk Potential NIPT Test Market Size and Forecast

6. United States Non–Invasive Prenatal Testing Market Growth Drivers and Challenges
6.1 Key Market Growth Drivers
6.2 Key Market Challenges

7. Non–Invasive Prenatal Testing Comparative Analysis

8. Reimbursement Environment of the United States Non-Invasive Prenatal Testing Market

9. Regulation Framework of the United States Non-Invasive Prenatal Testing Market

10. Major Deals and Agreements in the Non–Invasive Prenatal Testing Market
10.1 Collaboration Deals
10.2 Venture Capital Investment
10.3 Mergers and Acquisitions
10.4 Exclusive Agreement
10.5 Licensing Agreement
10.6 Distribution Agreement
10.7 Partnership Deals

11. Key Companies Analysis
11.1 Integrated Genetics (LabCorp)
11.1.1 Business Overview
11.1.2 Product Outlook
11.1.3 Key Developments
11.2 Yourgene Health
11.2.1 Business Overview
11.2.2 Product Outlook
11.2.3 Key Developments
11.3 Ariosa Diagnostics (Roche)
11.3.1 Business Overview
11.3.2 Product Outlook
11.3.3 Key Developments
11.4 Illumina
11.4.1 Business Overview
11.4.2 Product Outlook
11.4.3 Key Developments
11.5 Natera
11.5.1 Business Overview
11.5.2 Product Outlook
11.5.3 Key Developments
11.6 Quest Diagnostics
11.6.1 Business Overview
11.6.2 Product Outlook
11.6.3 Key Developments
11.7 Myriad Genetics
11.7.1 Business Overview
11.7.2 Product Outlook
11.7.3 Key Developments
11.8 Centogene
11.8.1 Business Overview
11.8.2 Product Outlook
11.8.3 Key Developments
11.9 Invitae Corporation
11.9.1 Business Overview
11.9.2 Product Outlook
11.9.3 Key Developments
11.10 GenPath
11.10.1 Business Overview
11.10.2 Product Outlook
11.10.3 Key Developments
11.11 Progenity
9.11.1 Business Overview
11.11.1 Product Outlook
11.11.2 Key Developments
11.12 PerkinElmer
11.12.1 Business Overview
11.12.2 Product Outlook
11.12.3 Key Developments
11.13 Agilent Technologies
11.13.1 Business Overview
11.13.2 Product Outlook
11.13.3 Key Developments

List of Tables:

Table 6–1: Maternal Age at Delivery and Risk of Down Syndrome
Table 7–1: Non–Invasive Prenatal Testing – Comparative Tests Analysis
Table 10–1: Collaboration Deals in the Non–Invasive Prenatal Testing Market
Table 10–2: Venture Capital Investment in the Non–Invasive Prenatal Testing Market
Table 10–3: Merger & Acquisition in the Non–Invasive Prenatal Testing Market
Table 10–4: Exclusive Agreement in the Non–Invasive Prenatal Testing Market
Table 10–5: Licensing Agreement in the Non–Invasive Prenatal Testing Market
Table 10–6: Distribution Agreement in the Non–Invasive Prenatal Testing Market
Table 10–7: Partnership Deals in the Non–Invasive Prenatal Testing Market

List of Figures:

Figure 2–1: United States Actual NIPT Test Volume (Thousand),2015 – 2020
Figure 2–2: United States Actual NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 2–3: United States Average Risk Actual NIPT Test Volume (Thousand),2015 – 2020
Figure 2–4: United States Average Risk Actual NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 2–5: United States High-Risk Actual NIPT Test Volume (Thousand),2015 – 2020
Figure 2–6: United States High-Risk Actual NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 3–1: United States Potential NIPT Test Volume (Thousand),2015 – 2020
Figure 3–2: United States Potential NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 3–3: United States Average Risk Potential NIPT Test Volume (Thousand),2015 – 2020
Figure 3–4: United States Average Risk Potential NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 3–5: United States High-Risk Potential NIPT Test Volume (Thousand),2015 – 2020
Figure 3–6: United States High-Risk Potential NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 4–1: United States Actual NIPT Test Market Size (Million US$),2015 – 2020
Figure 4–2: United States Actual NIPT Test Market Size Forecast (Million US$),2021 – 2028
Figure 4–3: United States Average Risk Actual NIPT Test Market Size (Million US$),2015 – 2020
Figure 4–4: United States Average Risk Actual NIPT Test Market Size Forecast (Million US$),2021 – 2028
Figure 4–5: United States High-Risk Actual NIPT Test Market Size (Million US$),2015 – 2020
Figure 4–6: United States High-Risk Actual NIPT Test Market Size Forecast (Million US$),2021 – 2028
Figure 5–1: United States Potential NIPT Test Market Size (Million US$),2015 – 2020
Figure 5–2: United States Potential NIPT Test Market Size Forecast (Million US$),2021 – 2028
Figure 5–3: United States Average Risk Potential NIPT Test Market Size (Million US$),2015 – 2020
Figure 5–4: United States Average Risk Potential NIPT Test Market Size Forecast (Million US$),2021 – 2028
Figure 5–5: United States High-Risk Potential NIPT Test Market Size (Million US$),2015 – 2020
Figure 5–6: United States High-Risk Potential NIPT Test Market Size Forecast (Million US$),2021 – 2028

 

  • Atrophic Vaginitis (Vaginal Atrophy-Vulvovaginal Atrophy-Urogenital Atrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
    Published: 02-May-2022        Price: US 2000 Onwards        Pages: 38
    Atrophic Vaginitis (Vaginal Atrophy-Vulvovaginal Atrophy-Urogenital Atrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) pipeline landscape. The report pro......
  • Premature Ovarian Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
    Published: 02-May-2022        Price: US 2000 Onwards        Pages: 39
    Premature Ovarian Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Premature Ovarian Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Premature Ovarian Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Premature Ovarian Failure, complete with analysis by Stage of Development, Drug......
  • Vasomotor Symptoms of Menopause (Hot Flashes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
    Published: 02-May-2022        Price: US 2000 Onwards        Pages: 42
    Vasomotor Symptoms of Menopause (Hot Flashes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Vasomotor Symptoms of Menopause (Hot Flashes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vasomotor Symptoms ......
  • Born Small For Gestational Age (SGA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
    Published: 02-May-2022        Price: US 2000 Onwards        Pages: 35
    Born Small For Gestational Age (SGA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Born Small For Gestational Age (SGA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Born Small For Gestational Age (SGA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Born Small For Gestational Age (SGA), complete......
  • Menopausal Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
    Published: 02-May-2022        Price: US 2000 Onwards        Pages: 51
    Menopausal Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Menopausal Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Menopausal Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Menopausal Disorders, complete with analysis by Stage of Development, Drug Target, Mechanism o......
  • 2022-2029 Global Bacterial Vaginosis Drug Professional Market Research Report, Analysis from Perspective of Segmentation (Competitor Landscape, Type, Application, and Geography)
    Published: 26-Apr-2022        Price: US 2980 Onwards        Pages: 123
    The Bacterial Vaginosis Drug market has witnessed growth from USD XX million to USD XX million from 2017 to 2022. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2029. The report focuses on the Bacterial Vaginosis Drug market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides detailed cost analysis, supply chain. Techno......
  • 2022-2030 Report on Global Bacterial Vaginosis Drug Market by Player, Region, Type, Application and Sales Channel
    Published: 18-Apr-2022        Price: US 2500 Onwards        Pages: 115
    This report studies the Bacterial Vaginosis Drug market, covering market size for segment by type (Rx, OTC, etc.), by application (Hospital, Pharmacy, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Bayer, Pfizer, Sanofi, Piramal, Abbott, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Bacterial Vaginosis Drug from 2016-2021, and prov......
  • 2022-2029 Global Tocolysis Drugs Professional Market Research Report, Analysis from Perspective of Segmentation (Competitor Landscape, Type, Application, and Geography)
    Published: 12-Apr-2022        Price: US 2980 Onwards        Pages: 103
    The Tocolysis Drugs market has witnessed growth from USD XX million to USD XX million from 2017 to 2022. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2029. The report focuses on the Tocolysis Drugs market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides detailed cost analysis, supply chain. Technological innovation......
  • Male Hypogonadism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 31-Mar-2022        Price: US 2000 Onwards        Pages: 83
    Male Hypogonadism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape. Male hypogonadism is a condition in which the body doesn't produ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs